. Patients typically respond to treatment with antibiotics such as vancomycin or metronidazole, but recurrence occurs in 25-30% of patients 6 and, in 2011, the infection was linked to 29,000 US deaths 5 . Because CDI is a toxin-mediated disease, a structural and mechanistic understanding of toxin function is a significant priority for the development of novel anti-toxin therapeutics.
TcdA and TcdB are large (308 and 270 kDa, respectively), homologous (47% amino acid identity) proteins with four functional domains that contribute to a multi-step mechanism of entry 4 ( Fig. 1a) . The C-terminal combined repetitive oligopeptides (CROPS) domain contributes to a cell-surface binding event [7] [8] [9] , which is followed by receptor-mediated endocytosis 10, 11 . The low pH of the endosome promotes the membrane insertion of the central delivery domain, allowing for pore formation [11] [12] [13] . The N-terminal glucosyltransferase domain (GTD) is translocated across the membrane and released into the host cell cytosol where it can inactivate small GTPases such as RhoA, Rac1 and Cdc42 14, 15 . Release of the GTD from the rest of the toxin is triggered when eukaryotic inositol-hexakisphosphate (InsP6) binds the autoprocessing domain (APD) and activates an intramolecular cleavage reaction 16, 17 . Although efforts to obtain well-diffracting crystals of either the TcdA or TcdB holotoxins have been unsuccessful, low-resolution structures of TcdA and TcdB have been determined by electron microscopy (EM) and small-angle X-ray scattering, respectively 18, 19 . EM analysis of TcdA and TcdB revealed that the elongated solenoid structure of the CROPS 8, 20, 21 can adopt multiple conformational states relative to the rest of the protein 18 , so we generated a TcdA construct with the CROPS deleted (TcdA 1832 ) for crystallization. The structure was determined and refined to 3.25 Å resolution (Supplementary Table 1 and Supplementary Fig. 1 ), and reveals significant interactions between the GTD and APD and an extended and topologically complex delivery domain ( Fig. 1b and Supplementary Video 1). The last residue visible in the TcdA 1832 structure is S1802. Clear placement of the TcdA 4-1802 structure into the holotoxin EM structure 18 (Fig. 1d) indicates that the CROPS extends from the base of the APD and could impact InsP6 binding. This is consistent with reports that the CROPS interacts with N-terminal sequences of TcdA to repress autoprocessing activity 22, 23 and our observation that a shorter construct (TcdA 1795 ) undergoes autoprocessing more efficiently than TcdA and TcdA 1832 ( Supplementary Fig. 2 ).
The GTD (residues 1-542) is responsible for transferring a glucose from UDP-glucose to the switch I region of Rho-family GTPases and is similar to the structures of the isolated GTDs from TcdA, TcdB and other large glucosylating toxins (Supplementary Table 2 ). In the context of TcdA 1832 , the GTD is oriented such that the GTPase binding site (proposed based on mutational studies in the TcdB GTD) 24 is occluded by the presence of the APD (Fig. 1c) . This explains data indicating that glucosyltransferase efficiency is enhanced after the GTD is released by autoprocessing 25 . The C-terminus of the GTD emerges in proximity to the APD (residues 543-802), with residues 538-557 forming an extended loop that spans the APD active site (Fig. 2a) .
Autoprocessing in TcdA and TcdB has been ascribed to an InsP6-dependent cysteine protease activity that results in cleavage after L542 (L543 for TcdB) and release of the GTD 16, 17, 26, 27 . Structures of the isolated TcdA and TcdB APDs have shown that InsP6 binds a positively charged pocket, distal from the active site [28] [29] [30] . Structures in the absence of InsP6 have heretofore been unavailable, but mutational studies have revealed an allosteric switch where InsP6 binding is functionally coupled to the active site through a central 'β-flap' structure ( Fig. 2b ) 28, 30 .
The N-terminal portion (547-741) of the TcdA 1832 APD (crystallized in the absence of InsP6) aligns to the InsP6-bound APD with an alpha-carbon root-mean squared deviation (r.m.s.d.) of 0.67 Å, but the C-terminal portion of the domain is significantly different. The β-flap (residues 746-765) separating the InsP6 binding site and the catalytic dyad (C700 and H655) has rotated ∼90°and the sequence that follows (766-802) is significantly repositioned (Fig. 2a,b and Supplementary Video 2). One effect of this conformational change is an increase in positively charged residues at the InsP6 binding site. The pocket transitions from four lysine residues in the TcdA 1832 structure (K602, K649, K754 and K777) to include seven lysines and one arginine in the InsP6 bound structure (Fig. 2a,b) , and thus provides a mechanistic framework for understanding how an electropositive InsP6 binding site can exist in the absence of InsP6. The largest change is evident in Lys766, as its NZ atom moves 21 Å as a result of rearrangements in the β-flap. The change also results in a 19 Å movement of H759 out of the active site (comparison of Cβ atoms). Mutation of H759 (or H757 from TcdB) results in a protein whose autoprocessing profile no longer varies with InsP6 concentration (Fig. 2c) , suggesting that this residue is a key regulator of InsP6-induced allostery in TcdA and TcdB.
Analysis of anomalous signals in our diffraction data revealed a zinc atom, bound at H759 and the catalytic dyad of the APD (Fig. 2a and Supplementary Fig. 3a) . TcdA binds zinc in solution, as indicated by both X-ray absorption spectroscopy (XAS) and inductively coupled plasma-mass spectrometry (ICP-MS) experiments ( Supplementary Fig. 3b and Supplementary Table 3) . A zinc atom is present at this site in both TcdA and TcdB, as indicated by ICP-MS analysis of TcdA, TcdB and catalytic dyad mutants (C700A and H655A or C698A and H653A in TcdA and TcdB, respectively) (Supplementary Table 3 ). One interpretation for the observation of zinc bound at this site is that zinc acts as an inhibitor of autoprocessing. InsP6 binding could displace His759 (or TcdB His757), causing the release of zinc and the availability of cysteine as a nucleophile. However, the addition of InsP6 to TcdA or TcdB did not displace zinc from the active site (Supplementary  Table 3 ). Furthermore, the removal of the zinc through chelation with N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) resulted in a loss of autoprocessing activity that could then be restored through the addition of zinc (Fig. 2d,f ) . Even the TcdA H759A and TcdB H757A mutants that retain zinc binding (Supplementary Table 3 ) were rendered inactive for autoprocessing through treatment with TPEN (Fig. 2e) . These experiments indicate that zinc is required for the autoprocessing activity of TcdA and TcdB.
A three-helix bundle (767-841) is located at the GTD-APD interface and serves as a transition into the delivery domain (Fig. 3a) . The three-helix bundle is followed by a small globular sub-domain (850-1025) and then an elongated 'hydrophobic helical stretch' containing four α-helices (1026-1135) that extend to the other end of the molecule. The delivery domain then adopts a series of β-sheet structures as it returns to the base of the APD ( Supplementary Fig. 4) . A search for structural homologues using DALI indicates that the delivery domain structure is unique.
The hydrophobic sequences in TcdA (958-1130) and TcdB (956-1128) have been predicted to insert into the endosomal membrane with acidic pH to facilitate the translocation of the GTD into the cytosol 31 . Residues within this stretch have been shown experimentally to be important for TcdB pore formation, and the corresponding residues in TcdA are highlighted in Fig. 3a 32, 33 . Recognizing that hydrophobic helical elements resemble motifs present in the pore-forming domain of diphtheria toxin (DT) 34, 35 , Zhang et al. proposed a 'double-dagger' model where TcdB inserts two pairs of helical hairpins into the membrane to form a pore 32 . The pore-forming domain of DT is a globular 10-helix bundle, with the most hydrophobic sequences shielded within the core of the soluble toxin structure, while the helical hydrophobic sequences of TcdA are stretched across the surface of an elongated scaffold of β-sheets. We propose that this large delivery domain scaffold provides an alternative structural solution to maintaining hydrophobic segments that are destined for the membrane in a soluble, but readily accessible conformation.
In addition to the homology with TcdB, TcdA shares homology with large glucosylating toxins from C. sordellii (TcsH and TcsL), C. novyi (Tcnα) and C. perfringens (TpeL). Sequences from these six large clostridial toxins (LCTs) were aligned and the sequence conservation was mapped onto the TcdA 1832 structure (Fig. 3b) . The largest area of strict conservation that mapped to the surface of the structure was located in a portion of the 'hydrophobic helical stretch', a 1096-1115 loop that includes the L1108-N1111 β-hairpin. We mutated the β-hairpin turn from VNN to SAS (a conservative change that maintains two small polar residues). TcdA SAS showed no defect in its cell surface binding ( Fig. 3c and Supplementary Fig. 5 ) or in vitro glucosyltransfer activity ( Fig. 3d and Supplementary Fig. 5 ) but was impaired in its capacity to kill cells (Fig. 3e) . TcdA SAS is impaired in a cell-surface Rb + release assay (Fig. 3f ) and in its capacity to glucosylate Rac1 in a cellbased intoxication assay (Fig. 3c) , suggesting a defect in endosomal membrane insertion. The identification of a conserved surface turn with essential function in toxicity suggests that antibodies specific for this conserved region could provide protection against multiple toxin-mediated clostridial infections and points to a generalizable strategy for generating safe vaccine antigens for this class of toxins.
Methods
Plasmid construction and point mutants. Previously described plasmids for the recombinant expression of TcdA (ref. 25) , TcdA 1832 (ref. 25) and TcdB (ref. 18 ) were used as templates for all mutant proteins generated for this study. Mutations were introduced by site-directed mutagenesis using the QuickChange protocol (Supplementary Table 4 ). TcdB C698A and TcdB H653A have been described previously 38 . The plasmid encoding TcdA DXD (ref. 27 ) was provided by Ralf Gerhard (Hannover Medical School).
Protein expression and purification. GST-Rac1 was expressed and purified as described previously 25 . Toxin expression plasmids were transformed into B. megaterium protoplasts according to the manufacturer's protocol (MoBiTec).
Transformants were grown in Luria-Bertani (LB) broth containing 10 µg ml -1 tetracycline at 37°C and 220 r.p.m. overnight to produce a seed culture. To 1 l of LB, 30 ml of the overnight seed was used as inoculum. The inoculated cultures were grown at 37°C until an optical density of 0.3-0.4 at 600 nm was reached. Protein expression was induced using 5 g l -1 of D-xylose solid (TCI, X0019). After a further ∼4 h more at 37°C and 220 r.p.m., the cells were harvested into 1 l bottles at 4°C and 5,000g for 30 min. Pellets were resuspended in buffer containing 20 mM Tris, pH 8.0, 300 mM NaCl, 10 µg ml -1 DNaseI, protease cocktail (Sigma, P8849) and 20 µg ml -1 lysozyme. The suspensions were homogenized using a dounce homogenizer and then lysed at room temperature at 25,000 psi (Constant Cell Disruption Systems). The lysates were placed on ice then centrifuged at 18,000 r.p.m. in a JA-20 fixed-angle rotor for 25 min at 4°C. After filtering the chilled supernatants through 0.22 mm filters, the proteins were purified using nickel affinity chromatography at 4°C. Further purification was performed at room temperature using anion exchange chromatography followed by gel-filtration chromatography into either 20 mM Tris, pH 8.0, 100 mM NaCl (for crystallization) or 20 mM HEPES pH 6.9, 50 mM NaCl for cell-based experiments.
Crystallization. TcdA 1832 and S1329C TcdA 1832 were concentrated to 10 mg ml -1 in 20 mM Tris, pH 8.0, 100 mM NaCl. Crystallization was performed using the hanging drop method at 21°C with a 1:1 ratio of protein to mother liquor. The mother liquor formulation for wild-type (WT) crystals was 100 mM Bis-Tris, pH 6, 11% PEG 4000, 30-50 mM guanidium chloride (GuCl). The mother liquor formulation for the S1329C crystals was 100 mM Bis-Tris, pH 5.8, 8% PEG 4000, 50 mM GuCl. Crystals were exchanged into appropriate mother liquor containing 20% glycerol, mounted on cryo loops and flash-cooled in liquid nitrogen.
Heavy atom derivatives of TcdA 1832 were prepared by soaking crystals in the appropriate mother liquor containing either 5 mM mercuric chloride for 90 min, 5 mM mercuric chloride for 3 days, 1 mM gold (III) chloride hydrate for 40 min, or 1 mM K 2 PtCl 2 for 40 min. Heavy atom derivatives of S1329C TcdA 1832 were prepared by soaking crystals in 5 mM mercuric chloride for 3 days.
Structure determination and refinement. X-ray data were collected from single crystals on LS-CAT beamline 21 ID-D at the Advanced Photon Source (Argonne, IL) at 100 K. Diffraction data were indexed, integrated and scaled using X-ray Detector Table 1 ). The two mercury data sets were compared to the native data set using multiple isomorphous replacement with anomalous scattering in SHARP (ref. 41 ). The analysis revealed five mercury sites in the two mercury data sets, differing only in their occupancies, and was consistent with the expectation that each protein monomer would have five free cysteine residues. The heavy atom positions were used to calculate initial phases, which were included in an auto-building protocol in PHENIX (ref. 42 ). The fragments generated by auto-building guided manual placement of the apo-GTD structure (PDB ID 3SS1) 25 . Phases from the GTD model were combined with the phases from SHARP to calculate a new map and initiate a new round of autobuilding. The fragments generated through autobuilding allowed for manual placement of the APD (PDB ID 3H06) 28 . Phases from the combined GTD and APD model were combined with the phases from SHARP to calculate a new map and initiate new rounds of automated and manual building. Further phase improvement came from multi-crystal averaging. The working model (consisting of the GTD, most of the APD and a series of unconnected fragments from the delivery domain) was used as search model for molecular replacement into the native, platinum and gold data sets. The models and phases from each data set were subjected to multi-crystal averaging and density modification in PHENIX and resulted in excellent quality maps. One area of ambiguity was resolved through sitespecific introduction of a mercury atom: crystals of a S1329C TcdA1-1832 mutant were derivatized with mercuric chloride, and the sixth heavy atom site was identified using PHENIX. The model was generated through an iterative process of manual building in Coot (ref. 43 ) and refinement using Phenix 42 . The final model reflects the 50-3.25 Å native data set (R-factor = 18.2%, free R-factor = 23.7%) with 92.3% of the residues in the most favoured regions of the Ramachandran plot with 0.6% outliers. The model contains residues 4-944 and 951-1802 along with one zinc atom.
X-ray absorption spectroscopy. XAS experiments were carried out at beamline X3B of the National Synchrotron Light Source, which was equipped with a sagitally focused Si(111) double-crystal monochromator and a nickel-coated mirror for harmonic rejection. A helium Displex cryostat was used for temperature control (∼15 K typical sample temperatures). Fluorescence detection was provided by a 31-element solid-state germanium detector array (Canberra). Samples of TcdA (10 mg ml 1025 and 1136-1802 ) is depicted as a transparent surface with the GTD in white and the APD in blue. The delivery domain is visible as a cartoon to highlight the three-helix bundle (blue), the globular sub-domain (green), the α-helical hydrophobic stretch (residues 1026-1135, pink) and the β-scaffold (yellow). Residues implicated in TcdB pore formation are shown as orange 33 or red 32 sticks. b, Representative sequences from the six large clostridial glycosylating toxins were aligned and scored with a Risler matrix according to the extent of sequence variation. Scores are displayed on the TcdA 1832 structure surface with a colour ramp (red, orange, yellow, green, light blue, dark blue) in which strictly conserved residues are coloured red and the most variable residues are coloured dark blue. The most conserved surface region (boxed) is at the end of the α-helical hydrophobic stretch: the 1098-1118 loop and β-hairpin. Within this region, the V1109, N1110 and N1111 residues are notable in their accessibility to solvent. c, The TcdA SAS protein binds cells at levels equivalent to wild type but is impaired in its capacity to glucosylate Rac1. Toxins (10 nM) were applied to HeLa cells and incubated for 3 h at 37°C. Proteins were separated by SDS-PAGE and probed with antibodies that recognize TcdA CROPS, non-glucosylated Rac1 or total Rac1. Quantitation of four gels indicates that while 100% of the detectable Rac1 was glucosylated by TcdA, only 23.4 ± 10.8% was glucosylated by TcdA SAS (relative to mock treated). d, The TcdA SAS protein is not impaired in its capacity to glucosylate Rac1 in vitro using purified proteins. Toxins (100 nM) were incubated with purified GST-Rac1 for 3 h at 37°C and analysed as in c. The gel is representative of three independent experiments. e, The TcdA SAS mutant is defective in its cellular toxicity. Toxins (10 fM-20 nM) were incubated with CHO cells for 48 h at 37°C and viability was normalized to untreated cells. A representative dose-response curve is shown and values of the effective concentration conferring half maximal protection (EC 50 ) ± s.d. were calculated from two biological replicates using Prism: TcdA (blue circles, EC 50 = 0.11 ± 0.01 nM); TcdA DXD (a glucosyltransferase-defective mutant the X-ray beam (incident energy = 10 keV) were examined. There was a significant increase in the total zinc fluorescence counts for the TcdA sample compared with buffer, while fluorescence for the Mn-Cu series was unchanged. XAS measurements were therefore carried out at the zinc K-edge on TcdA, over an energy range of 9.46-10.3 keV. Internal energy calibration was provided by simultaneous measurement of a zinc metal foil, with the first inflection point of the edge set to a reference energy of 9,659 eV. Calibration and averaging of XAS data were carried out using Athena
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ICP-MS. Proteins were prepared as described above and dialysed overnight into metal-free buffers: 20 mM HEPES pH 6.9, 50 mM NaCl or 100 mM Bis-Tris pH 6.0, 50 mM NaCl at 4°C. Samples analysed in the presence of InsP6 were dialysed in buffer containing 10 mM InsP6. Samples analysed in the presence of TPEN were dialysed in 1 mM TPEN for 8 h at room temperature. Buffers containing 10 µM ZnCl 2 and 1 mM TCEP were used to add zinc back to the protein. Protein samples were analysed for metal content by using 50 µl of the protein solution and diluting in 2.5% (vol/vol) nitric acid (Sigma-Aldrich, TraceSELECT quality) to a final volume of 3 ml for ICP-MS analysis. In samples with significant precipitation after acidification, the samples were centrifuged at 15,000g for 20 min to pellet any precipitate, and the solution was transferred to a fresh tube for measurement. Ni using a 1-30 ppb standard curve using stock solutions (Perkin Elmer). Analyses were performed using a PerkinElmer ELAN DRCII ICP-MS. The instrument was equipped with a Microflow PFA-ST concentric nebulizer with a 100 µl min -1 self-aspiration capillary, a cyclonic spray chamber, a quartz torch and nickel sampler/skimmer cones. Germanium at 50 ppb was added as an internal standard using an EzyFit glass mixing chamber. Concentrations (in ppb) were corrected for the dilution factor, and the molar concentrations and molar ratios ( 66 Zn/protein) were determined for each sample.
Autoprocessing assays. Assays were performed as described previously 38 . Reactions testing the effect of TPEN were pre-incubated with 10 mM TPEN at 37°C for 2 h before the addition of InsP6. Autoprocessing assays with samples also analysed by ICP-MS were performed in the appropriate dialysate and indicated reactions contained 100 nM InsP6 pre-treated with TPEN to remove zinc from the InsP6 stock solution. Gels were quantified using ImageJ 45 . The intensity associated with cleaved GTD was divided by the intensity for the intact protein in the absence of InsP6.
Cell lines. Chinese hamster ovary (CHO-K1), HeLa and Vero cells were authenticated and verified to be mycoplasma-free at the time of purchase from ATCC and were aliquoted into primary frozen stocks. Experiments were conducted in cells passaged less than 30 times from the frozen stock.
Viability assays. CHO-K1 cells were cultured in Ham's F-12 medium with 10% FBS and 1% penicillin and streptomycin and seeded at a concentration of 8,000 cells per well in 96-well CellBind plates. The next day, medium was exchanged with serumfree medium and cells were intoxicated by adding TcdA toxins at a serial dilution of 1/3 starting at 10 nM. After intoxication, cells were incubated at 37°C, 5% CO 2 for 48 h. FBS was added back to cells 24 h after intoxication to a final concentration of 10% (vol/vol). The cell viability after 48 h was assessed by PrestoBlue Cell Viability Reagent (Life Technologies). Fluorescence was read on a Spectramax M5 plate reader (Molecular Devices).
Rubidium release assays. (PerkinElmer) at a density of 1 × 10 5 cells per well. Cells were incubated at 37°C, 5% CO 2 overnight. Medium was exchanged with fresh growth medium with 100 nM bafilomycin A1 (Sigma) and continued to incubate for another 20 min. Cells were then chilled on ice and ice-cold medium containing TcdA mutants (10 nM) was added. Cells were kept on ice for toxin binding for 1 h at 4°C before they were washed with ice-cold PBS twice to remove unbound toxins. pH-dependent insertion into the plasma membrane was induced by warm, acidified growth medium (37°C, pH 4.8 or pH 7.5) for 5 min at 37°C. Cells were incubated further on ice, medium containing released 86 
Rb
+ was removed from the cell plate at different time points, and the amount of Cell binding and Rac1 glucosylation in cells. HeLa cells were synchronized by cooling to 4°C and then intoxicated with 10 nM toxin or buffer. The cells were returned to 4°C for 1 h and then shifted to 37°C for 3 h. The cells were harvested and lysed (250 mM sucrose, 10 mM Tris pH 7.5, 3 mM imidazole), samples were boiled, and proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE). Samples were analysed by western blot with primary antibodies specific for TcdA CROPS (Abcam, ab19953), unglucosylated Rac1 (BD, 610650) and total Rac1 (Millipore, clone 23A8). Binding of an anti-mouse, HRP-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 115-035-174) was detected with a LumiGLO kit (Cell Signaling) according to the manufacturer's instructions.
Rac1 glucosylation in vitro. Toxin (100 nM) was added to 0.8 μM GST-Rac1 and 25 μM UDP-glucose (Sigma) in glucosylation buffer (50 mM HEPES pH 6.9, 100 mM KCl, 2 mM MgCl 2 , 1 mM MnCl 2 ) for 3 h. The reactions were stopped by adding Laemmli buffer and boiling. Samples were separated by SDS-PAGE and analysed by western blot using antibodies specific for glucosylated and total Rac1.
Statistical analyses. No statistical method was used to predetermine the sample size. Error bars displayed throughout the manuscript represent standard deviation (s.d.) and were calculated from biological replicates. No data were excluded from analysis. The number of replicates for each experiment is indicated in the figure legends.
Accession numbers. The coordinates for TcdA 1832 have been deposited in the Protein Data Bank (PDB) database under accession number 4R04.
